Shukra Pharmaceuticals Ltd

Company Profile

Shukra Pharmaceuticals Ltd had its IPO on under the ticker symbol SHUKRAPHAR.

The company operates in the sector and industry. Shukra Pharmaceuticals Ltd has a staff strength of 0 employees.

Stock update

Shares of Shukra Pharmaceuticals Ltd opened at ₹168.85 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹168.85 - ₹172.2, and closed at ₹172.2.

This is a +1.98% increase from the previous day's closing price.

A total volume of 795 shares were traded at the close of the day’s session.

In the last one week, shares of Shukra Pharmaceuticals Ltd have increased by +15.49%.

Shukra Pharmaceuticals Ltd's Key Ratios

Shukra Pharmaceuticals Ltd has a market cap of ₹156.41 million, indicating a price to book ratio of 1.2807 and a price to sales ratio of 0.8653.

In the last 12-months Shukra Pharmaceuticals Ltd’s revenue was ₹0 with a gross profit of ₹87.77 million and an EBITDA of ₹0. The EBITDA ratio measures Shukra Pharmaceuticals Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Shukra Pharmaceuticals Ltd’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.

In Q4, Shukra Pharmaceuticals Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Shukra Pharmaceuticals Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

309.2879

PEG

Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Shukra Pharmaceuticals Ltd’s profitability.

Shukra Pharmaceuticals Ltd stock is trading at a EV to sales ratio of 0.8891 and a EV to EBITDA ratio of 6.2584. Its price to sales ratio in the trailing 12-months stood at 0.8653.

Shukra Pharmaceuticals Ltd stock pays annual dividends of ₹0.5 per share, indicating a yield of 0.48% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹314.26 million

Total Liabilities

₹99.97 million

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

0%

Shukra Pharmaceuticals Ltd ended 2024 with ₹314.26 million in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹314.26 million while shareholder equity stood at ₹167.54 million.

Shukra Pharmaceuticals Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹99.97 million in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹11.15 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹13.95 million.

Shukra Pharmaceuticals Ltd’s total current assets stands at ₹112.70 million while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹30.61 million compared to accounts payable of ₹83.95 million and inventory worth ₹27.95 million.

In 2024, Shukra Pharmaceuticals Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Shukra Pharmaceuticals Ltd paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price

₹172.2

52-Week High

₹219.2612

52-Week Low

₹41.76

Analyst Target Price

₹

Shukra Pharmaceuticals Ltd stock is currently trading at ₹172.2 per share. It touched a 52-week high of ₹219.2612 and a 52-week low of ₹219.2612. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹148.41 and 200-day moving average was ₹119.85 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.